(MRKR)

NCM – Цена в реальном времени. Валюта: USD

1.30

-0.05 (-3.70%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

1.30

0.00 (0.00%)

После закрытия: Mar 27, 2026, 4:10 PM EDT

18.03.2026

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

MARKER THERAPEUTICS, INC. (MRKR) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.21.

18.03.2026

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses

18.02.2026

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event: Oppenheimer 36 th Annual Healthcare Life Sciences Conference Date: Wednesday, February 25, 2026 Time: 8:00 – 8:30 a.m.

21.01.2026

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.

07.01.2026

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

After reaching an important support level, MARKER THERAPEUTICS, INC. (MRKR) could be a good stock pick from a technical perspective.

07.01.2026

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.

05.01.2026

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study

Видео

No Data

There is no data to display

(MRKR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

(MRKR)

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Видео

No Data

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Видео

No Data